NO20054411D0 - Terapeutiske midler omfattende et anti-angiogent middel i kombinasjon med en SRC-inhibitor og deres terapeutiske anvendelse - Google Patents

Terapeutiske midler omfattende et anti-angiogent middel i kombinasjon med en SRC-inhibitor og deres terapeutiske anvendelse

Info

Publication number
NO20054411D0
NO20054411D0 NO20054411A NO20054411A NO20054411D0 NO 20054411 D0 NO20054411 D0 NO 20054411D0 NO 20054411 A NO20054411 A NO 20054411A NO 20054411 A NO20054411 A NO 20054411A NO 20054411 D0 NO20054411 D0 NO 20054411D0
Authority
NO
Norway
Prior art keywords
combination
angiogenic agent
therapeutic
src inhibitor
therapeutic agents
Prior art date
Application number
NO20054411A
Other languages
English (en)
Other versions
NO20054411L (no
Inventor
Jon Owen Curwen
Stephen Robert Wedge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20054411D0 publication Critical patent/NO20054411D0/no
Publication of NO20054411L publication Critical patent/NO20054411L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20054411A 2003-05-07 2005-09-23 Terapeutiske midler omfattende et anti-angiogent middel i kombinasjon med en SRC-inhibitor og deres terapeutiske anvendelse NO20054411L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0310401.5A GB0310401D0 (en) 2003-05-07 2003-05-07 Therapeutic agent
PCT/GB2004/001939 WO2004098604A1 (en) 2003-05-07 2004-05-04 Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use

Publications (2)

Publication Number Publication Date
NO20054411D0 true NO20054411D0 (no) 2005-09-23
NO20054411L NO20054411L (no) 2005-11-30

Family

ID=9957542

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054411A NO20054411L (no) 2003-05-07 2005-09-23 Terapeutiske midler omfattende et anti-angiogent middel i kombinasjon med en SRC-inhibitor og deres terapeutiske anvendelse

Country Status (14)

Country Link
US (2) US20060223815A1 (no)
EP (1) EP1620104A1 (no)
JP (1) JP2006525304A (no)
KR (1) KR20060009893A (no)
CN (1) CN100418531C (no)
AU (1) AU2004237132B2 (no)
BR (1) BRPI0409742A (no)
CA (1) CA2519930A1 (no)
GB (1) GB0310401D0 (no)
MX (1) MXPA05011858A (no)
NO (1) NO20054411L (no)
NZ (1) NZ542348A (no)
WO (1) WO2004098604A1 (no)
ZA (1) ZA200508858B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
WO2004041829A1 (en) * 2002-11-04 2004-05-21 Astrazeneca Ab Quinazoline derivatives as src tyrosine kinase inhibitors
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
JP2007518823A (ja) 2004-01-23 2007-07-12 アムゲン インコーポレイテッド キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途
TW200536851A (en) 2004-01-23 2005-11-16 Amgen Inc Compounds and methods of use
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
KR20060130764A (ko) * 2004-03-23 2006-12-19 아스트라제네카 아베 병용 요법
GB0412074D0 (en) 2004-05-29 2004-06-30 Astrazeneca Ab Combination product
MX2007006230A (es) 2004-11-30 2007-07-25 Amgen Inc Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer.
GB0427697D0 (en) 2004-12-17 2005-01-19 Astrazeneca Ab Chemical process
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
CA2614002A1 (en) * 2005-07-06 2007-01-11 Astrazeneca Ab Combination therapy of cancer with azd2171 and gemcitabine
BRPI0614965A2 (pt) * 2005-08-26 2016-09-13 Antisoma Plc método para a modulação de crescimento neoplástico, usos de um composto ou, um sal, éster ou pró-droga farmaceuticamente aceitável do mesmo, de um aglutinante do fator de crescimento endotelial vascular, e de um taxano, formulação farmacêutica, e, kit
KR20080077678A (ko) * 2005-12-22 2008-08-25 아스트라제네카 아베 Ａｚｄ2171 및 페메트렉시드의 조합물
AU2008319366B2 (en) * 2007-10-29 2012-03-01 Amgen Inc. Benzomorpholine derivatives and methods of use
WO2009068906A2 (en) * 2007-11-26 2009-06-04 Astrazeneca Ab Combinations comprising zd4054 and a src family kinase inhibitor 172
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
JP6426195B2 (ja) * 2013-11-01 2018-11-21 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物の結晶形態及びその使用
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
KR100838617B1 (ko) * 1999-02-10 2008-06-16 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
SK2142003A3 (en) * 2000-08-21 2003-07-01 Astrazeneca Ab Quinazoline derivatives, process for their preparation, pharmaceutical composition comprising same and their use
WO2002092579A1 (en) * 2001-05-14 2002-11-21 Astrazeneca Ab 4-anilinoquinazoline derivatives
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
CA2495487A1 (en) * 2002-08-09 2004-02-19 Astrazeneca Ab Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
WO2004071397A2 (en) * 2003-02-13 2004-08-26 Astrazeneca Ab Combination therapy of zd6474 with 5-fu or/and cpt-11
GB0316123D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
CA2531862C (en) * 2003-07-10 2011-10-25 Astrazenca Ab Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
KR20060130764A (ko) * 2004-03-23 2006-12-19 아스트라제네카 아베 병용 요법
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
GB0412074D0 (en) * 2004-05-29 2004-06-30 Astrazeneca Ab Combination product
WO2006035203A1 (en) * 2004-09-27 2006-04-06 Astrazeneca Ab Cancer combination therapy comprising azd2171 and imatinib
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
JP4834985B2 (ja) * 2004-12-10 2011-12-14 日産自動車株式会社 組電池の容量調整装置

Also Published As

Publication number Publication date
US20060223815A1 (en) 2006-10-05
CN1784232A (zh) 2006-06-07
NO20054411L (no) 2005-11-30
AU2004237132B2 (en) 2007-10-18
BRPI0409742A (pt) 2006-05-09
AU2004237132A1 (en) 2004-11-18
GB0310401D0 (en) 2003-06-11
KR20060009893A (ko) 2006-02-01
MXPA05011858A (es) 2006-02-17
CN100418531C (zh) 2008-09-17
US20100029673A1 (en) 2010-02-04
JP2006525304A (ja) 2006-11-09
ZA200508858B (en) 2007-03-28
EP1620104A1 (en) 2006-02-01
NZ542348A (en) 2009-01-31
WO2004098604A1 (en) 2004-11-18
CA2519930A1 (en) 2004-11-18

Similar Documents

Publication Publication Date Title
NO20054411D0 (no) Terapeutiske midler omfattende et anti-angiogent middel i kombinasjon med en SRC-inhibitor og deres terapeutiske anvendelse
DK1891973T3 (da) Kombinationer omfattende antimuskarine midler og PDE4-hæmmere
DK1928457T3 (da) Quinoliner og deres terapeutiske anvendelse
DK2589599T3 (da) Hidtil ukendte hydroxy-6-heteroarylphenanthridiner og deres anvendelse som PDE4-inhibitorer
DK1954140T3 (da) Glycerollevulinatketaler og deres anvendelse
DK1917246T3 (da) Benzoquinazolinderivater og deres anvendelse til behandling af knoglesygdomme
DK1578755T3 (da) Phosphonooxyguinalinderivater og deres farmaceutiske anvendelse
HK1096092A1 (en) Benzamide derivatives and their use as glucokinase activating agents
IS7725A (is) Imidazólópyridín og aðferðir við framleiðslu og notkun þeirra
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
IS8392A (is) Heterósýklískir hindrar MEK og notkun þeirra
IS8329A (is) Kínólínafleiður og notkun þeirra í meðferð
NO20054453D0 (no) P38 inhibitorer og fremgangsmater for anvendelse derav
NO20033565L (no) Acylerte indanylaminer og deres anvendelse som farmasöytiske midler
ATE435859T1 (de) Gyraseinhibitoren und deren verwendungen
NO20044062L (no) N-aryl-2-oksazolidinon-5-karboksamider og deres derivater og deres anvendelse som antibakterielle midler
NO20044095L (no) 5-fenyltiazolderivater og anvendelse som P13 kinaseinhibitorer
NO20034388L (no) Terapeutisk middel for kronisk artritt sykdommer i barne- relaterte sykdommer
IS7977A (is) Samsetningar og aðferð til samsettra meðferðar
ATE423121T1 (de) Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren
NO20053593D0 (no) Arylalkylkarbamat-derivater, fremgangsmate og anvendelse derav i terapi
DK1771421T3 (da) N-hydroxyamidderivater og anvendelse deraf
DK1709018T3 (da) Acylaminothiazolderivater og anvendelse deraf som beta-amyloid-hæmmere
IS8597A (is) Samsetningar rísedrónats og aðferðir við notkun þess
DK1867332T3 (da) Farmaceutisk sammensætning og fremgangsmåde under anvendelse af et antimykotisk middel i kombination

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application